Clinical trials: Liraglutide
Obesity
The Effect of Liraglutide on the GIT
Liraglutide is a glucose-like peptide 1 agonist, currently used as an effective weight-loss treatment. Its mechanism of action has not yet been elucidated.
- Trial name
- LIRHV (NCT04008290)
- Testing
- 0.6 mg Liraglutide
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
Healthy
A Study of LY3537021 in Healthy Participants
The main purpose of this study is to evaluate the safety and tolerability of LY3537021 when administered in combination with glucagon-like peptide (GLP-1) receptor agonist called liraglutide in treatment-naïve healthy…
- Trial name
- NCT05444569
- Testing
- LY3537021, Liraglutide
- Where
- Singapore
- Volunteers
- 47 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Metabolic Syndrome
Effects of Exercise and GLP-1 Agonism on Muscle Microvascular Perfusion and Insulin Action in Adults With Metabolic Syndrome
The primary objective of this study is to examine whether exercise training alone, liraglutide treatment alone or exercise training plus liraglutide treatment increases cardiac and skeletal muscle microvascular blood volume…
- Trial name
- ZQL008 (NCT04575844)
- Testing
- Liraglutide, Exercise training, Liraglutide + Exercise training
- Where
- United States
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- University of Virginia
Diabetes, Diabetes Mellitus, Type 2
A Trial to Investigate the Single Dose Pharmacokinetics of Insulin Degludec/Liraglutide Compared With Insulin Degludec and Liraglutide in Healthy Chinese Subjects
The main purpose of the trial is to compare the bioavailability (extent of drug absorption into the circulation) of insulin degludec and liraglutide as part of a combination product insulin degludec/liraglutide compared to the…
- Trial name
- NCT03292185
- Testing
- insulin degludec/liraglutide, insulin degludec, liraglutide
- Where
- China
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S
Obesity
To Investigate the Safety, Tolerability and Pharmacodynamics of GSK2890457 in Healthy Volunteers and Subjects With Type 2 Diabetes
This study is the first administration of GSK2890457 in humans. The study will be conducted in 3 parts: - Part A (conducted at a single investigative site) will determine the safety and tolerability of GSK2890457 alone in healthy…
- Trial name
- NCT01725126
- Testing
- GSK2890457, Metformin, Liraglutide
- Where
- 3 sites in United States
- Volunteers
- 53 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Diabetes Mellitus, Type 2
A Study of LY3325656 in Healthy Participants and Participants With Type 2 Diabetes
The aim of this trial is to evaluate the safety of single doses of a study drug known as LY3325656 that is given orally to healthy participants and participants with type 2 diabetes.
- Trial name
- NCT03115099
- Testing
- LY3325656, Liraglutide, Sitagliptin
- Where
- 2 sites in Singapore
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Diabetes, Diabetes Mellitus, Type 2
Safety of Liraglutide in Subjects With Liver Impairment and in Subjects With Normal Liver Function
This trial is conducted in Europe. The aim of this trial is to investigate liraglutide in subjects with mild, moderate and severe degrees of hepatic impairment compared with subjects with normal hepatic function.
- Trial name
- NCT01507389
- Testing
- liraglutide
- Where
- Poland
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S
Diabetes, Healthy
Effect of Liraglutide on Gastrointestinal Absorption of Several Drugs and Potential Influence of Liraglutide on Intragastric pH
The trial is conducted in Europe. The aim of the trial is to investigate if there is any drug to drug interaction between liraglutide and atorvastatin (Lipitor®), lisinopril (Zestril®), griseofulvin and digoxin (Lanoxin®).
- Trial name
- NCT01518166
- Testing
- liraglutide, atorvastatin, lisinopril
- Where
- Sweden
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S
Obesity
The Effect of Liraglutide on Pancreatic Hormones and Its Size
Glucagon-like peptide-1 (GLP-1) is a gastrointestinal hormone used to treat type 2 diabetes and severe overweight (Liraglutide).The two pancreas enzymes: amylase and lipase are slightly elevated in GLP-1 treated compared with…
- Trial name
- LIRAP (NCT03520062)
- Testing
- Liraglutide (Saxenda) 6Mg/Ml Inj Pen 3Ml
- Where
- Denmark
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Nicolai Jacob Wewer Albrechtsen
Type 2 Diabetes, Obesity
The Microvascular Function of GLP-1 and Its Analogues
Incretins have become a successful drug target in the repertoire of medications used for the treatment of type 2 diabetes. However little is known about a potential benefit of GLP-1 on the vascular system in humans, independent…
- Trial name
- NCT01677104
- Testing
- GLP-1
- Where
- United Kingdom
- Volunteers
- 63 people, healthy volunteers welcome
- Sponsor
- Katarina Kos
Type 2 Diabetes, Peripheral Vascular Disorder Due to Diabetes Mellitus
Efficacy and Safety of Liraglutide in Type 2 Diabetes With Lower Extremity Arterial Disease
Diabetic lower extremity arterial disease ( DLEAD ), is a common complication of type 2 diabetes. However, DLEAD remains less studied than other diabetic vascular complications; and only few randomised controlled trials (RCTs)…
- Trial name
- NCT04146155
- Testing
- Liraglutide+standard-of-care treatment, standard-of-care treatment
- Where
- China
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Obesity
Combined Effects of GLP-1 Analogue and Exercise on Maintenance of Weight Loss and Health After Very-low Calorie Diet
Introduction: The success rate of weight loss maintenance is limited. Therefore, the purpose of this study is to investigate the maintenance of weight loss and immunometabolic health outcomes after diet-induced weight loss…
- Trial name
- S-LITE (NCT04122716)
- Testing
- Liraglutide, Exercise
- Where
- Denmark
- Volunteers
- 215 people, healthy volunteers welcome
- Sponsor
- Signe Torekov
Overweight, Obesity
3mg Liraglutide for Overweight or Obesity
In this study investigators will investigate the beneficial metabolic sequelae of Liraglutide in patients with obesity or overweight; including changes in vital signs, anthropometric characteristics (weight, body mass index and…
- Conditions
- Overweight, Obesity, Infertility, Female
- Trial name
- NCT03885297
- Testing
- Saxenda, Lifestyle modification, Metabolomics
- Where
- United Kingdom
- Volunteers
- 43 people, healthy volunteers welcome
- Sponsor
- University Hospitals Coventry and Warwickshire NHS Trust
Diabetes Mellitus, Type 2, Obesity
Holding vs. Continuing Incretin-based Therapies Before Upper Endoscopy
To assess whether holding incretin-based therapy before endoscopy reduces the likelihood of clinically relevant Residual Gastric Volume (RGV).
- Conditions
- Diabetes Mellitus, Type 2, Obesity, Gastroparesis
- Trial name
- NCT06533527
- Testing
- GLP-1 medication
- Where
- 2 sites in United States
- Volunteers
- 69 people, healthy volunteers welcome
- Sponsor
- The Cleveland Clinic
Obesity
Reward Mechanisms in Obesity
The study aims to investigate the effects of 3.0 mg of liraglutide on reward brain circuits in human obesity and to better understand its effects on weight loss (in patients without diabetes).
- Trial name
- LIRAOB (NCT03347890)
- Where
- Switzerland
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- Zoltan Pataky
Type 1 Diabetes
Anti-diabetic Effects of Liraglutide in Adolescents and Young Subjects With Type 1 Diabetes
This is the first prospective randomized double-blind placebo-controlled study to investigate the effect of a GLP-1 analog, specifically liraglutide, on blood glucose levels and variability in subjects with type 1 diabetes…
- Trial name
- NCT01722227
- Testing
- Liraglutide
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- University at Buffalo
Diabetes, Diabetes Mellitus, Type 2
Effect of Liraglutide on Heart Frequency in Healthy Volunteers
This trial is conducted in the United States of America (USA). The aim of this trial is to investigate if liraglutide effects the QTc interval. Moxifloxacin (Avelox®) is administered as positive control.
- Trial name
- NCT01516255
- Testing
- liraglutide, moxifloxacin, electrocardiogram (ECG)
- Where
- United States
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S
Diabetes, Diabetes Mellitus, Type 2
Safety and Tolerability of Liraglutide in Healthy Volunteers and Subjects With Type 2 Diabetes
This trial is conducted in Europe. The aim of this trial is to assess the safety and tolerability (maximum tolerated dose) after single and multiple doses of NNC 90-1170 (liraglutide) in healthy volunteers and in subjects with…
- Conditions
- Diabetes, Diabetes Mellitus, Type 2, Healthy
- Trial name
- NCT01507285
- Testing
- liraglutide
- Where
- United Kingdom
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S
Healthy Subjects
Incretin and KATP Channels
This study aims to examine the involvement of KATP channels on the microvascular actions of the incretin GLP-1 and its analogues in healthy individuals and to determine whether the acute oral administration of different KATP…
- Trial name
- NCT01934816
- Testing
- Intradermal injections of GLP-1 and its analogues
- Where
- United Kingdom
- Volunteers
- 2 people, healthy volunteers welcome
- Sponsor
- Katarina Kos
Type 1 Diabetes
Liraglutide in Type 1 Diabetes
The glucose lowering effects of GLP-1 agonists are well established in subjects with type 2 diabetes, however, these have not been studied prospectively in subjects with type 1 diabetes.
- Trial name
- 1966 (NCT01722240)
- Testing
- Liraglutide 1.8mg
- Where
- United States
- Volunteers
- 69 people, healthy volunteers welcome
- Sponsor
- University at Buffalo